Attention is rising on the progress of the two new asthma drugs that chose to receive reimbursement through the RSA track, unlike Cinquair.

According to industry sources, GSK Korea’s ‘Nucala (mepolizumab)’ has recently been reviewed by the Health Insurance Review and Assessment Service’s Risk Sharing Agreement (RSA) subcommittee for reimbursement. However, no news has been heard for AstraZeneca Korea’s Fasenra (benralizumab)’ yet.

Unlike Teva-Handok’s Cinqair (reslizumab), which opted to take the general reimbursement listing track, the two drugs faced difficulties after passing the Drug Reimbursement Evaluation Committee review in July.

If Cinqair completes drug p